PMV Pharmaceuticals, Inc.
Clinical trials sponsored by PMV Pharmaceuticals, Inc., explained in plain language.
A clinical-stage biotech developing precision oncology drugs targeting p53 mutations.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets rare cancer mutation in early trial Results expected Dec 2026 (estimated)
- New cancer Drug's interaction with other meds under scrutiny in early trial Results expected Mar 2027 (estimated)
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase 1/2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer Drug's interaction with other meds under scrutiny in early trial
Knowledge-focused Recruiting nowThis early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…
Phase 1 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC